
Releases
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit. The litigation, filed in the District of New Jersey, centers on allegations of undisclosed related-party transactions and revenue inflation.
























